MUSCLE RELAXANT AND ANALGESIC CAPLETS TABLET

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

IBUPROFEN; METHOCARBAMOL

Tilgjengelig fra:

INTERNATIONAL PHARMACEUTICAL GENERICS LTD

ATC-kode:

M03BA53

INN (International Name):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

Dosering :

200MG; 500MG

Legemiddelform:

TABLET

Sammensetning:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

Administreringsrute:

ORAL

Enheter i pakken:

100

Resept typen:

OTC

Terapeutisk område:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

Produkt oppsummering:

Active ingredient group (AIG) number: 0248961001; AHFS:

Autorisasjon status:

CANCELLED PRE MARKET

Autorisasjon dato:

2017-06-13

Preparatomtale

1 | P a g e
PRODUCT MONOGRAPH
MUSCLE RELAXANT & ANALGESIC CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
INTERNATIONAL PHARMACEUTICAL GENERICS LTD.,
Date of Preparation:
30 Malta Avenue, Suite 2408
February 01, 2010
Brampton, ON
L6Y 4S5
Control#: 135919
2 | P a g e
TABLE
OF CONTENTS
Clinical
Pharmacology..............................................................................................................................3
Indications:................................................................................................................................................7
Contraindications
......................................................................................................................................8
Warnings:..................................................................................................................................................8
Precautions..............................................................................................................................................12
Drug Interactions
....................................................................................................................................13
Adverse Reactions
..................................................................................................................................15
Symptoms and Treatment of
Overdose...................................................................................................17
Dosage and
Administration.....................................................................................................................18
Pharmaceutical
Information....................................................................................................................19
Composition:...........................................................................................................................................21
Availability of Dosage
Forms............